MM
Myles Minter
Compare →Biotech Equity Research Analyst at William Blair
Financial & Wall StreetBiotechnology
Myles Minter is a Biotech Equity Research Analyst at William Blair, specializing in the analysis of biotechnology companies. With a Ph.D. in neuropharmacology and a background in biomedical science, he transitioned from a postdoctoral role at the University of Chicago to equity research, where he focuses on commercial-stage biotech firms addressing high unmet medical needs.
No chart yet. A chart needs 8 resolved predictions, and Myles has 1. The predictions themselves are below.
SORT
STILL OPEN
?
2026 readouts across CRISPR, base editing, RNA editing and DNA writing will be significant.
Due Dec 31, 2026April 20, 2026gene editingbiotechPending
—
SCORE
?
2026 catalysts span base editing, RNA editing, allogeneic CAR-Ts, and DNA writing.
Due Dec 31, 2027April 20, 2026gene editingbiotechPending
—
SCORE
RESOLVED · NEWEST FIRST
✓
Vertex Pharmaceuticals will experience future earnings growth supported by an updated financial model that reflects an increase in the projected GAAP EPS.
May 3, 2024call #1biopharmaceuticalsfinancial growthCorrect
85
SCORE
Still open · 2
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
2026 readouts across CRISPR, base editing, RNA editing and DNA writing will be significant.
Due Dec 31, 2026Said April 20, 2026gene editingbiotech
?No market prices this claim
2026 catalysts span base editing, RNA editing, allogeneic CAR-Ts, and DNA writing.
Due Dec 31, 2027Said April 20, 2026gene editingbiotech